Copyright
©The Author(s) 2023.
World J Clin Oncol. Sep 24, 2023; 14(9): 324-334
Published online Sep 24, 2023. doi: 10.5306/wjco.v14.i9.324
Published online Sep 24, 2023. doi: 10.5306/wjco.v14.i9.324
Compounds | Mechanism | Ref. |
Elesclomol | Transferring copper ions to mitochondria and increasing ROS level | Nagai et al[7] |
Flavonoid drugs | Interfering with copper ion redox and inducing mitochondrial apoptosis | Liu et al[8] |
(Cu(DDC)2) | Inhibiting proteasome and leading to ER stress activation | Chen et al[9] |
Copper ion chelating agent | Inhibiting endothelial cell proliferation and angiogenesis | Zhou et al[15] |
Copper ion transporter inhibitor | Inhibit endothelial cell proliferation and angiogenesis | Yee et al[13], Karginova et al[14] |
NPs(Cu-CysNPs) | Reacting with glutathione to increase ROS level | Ma et al[18] |
Cu-TSC | Inducing ROS accumulation | Sîrbu et al[19] |
Cu-NSAID compound | Inducing ROS accumulation, DNA damage and COX-2 activity inhibition | Boodram et al[20] |
Copper complexes containing polypyridine ligands | Increasing ROS level and inducing ER stress | Kaur et al[21] |
- Citation: Wang J, Luo LZ, Liang DM, Guo C, Huang ZH, Sun GY, Wen J. Progress in the research of cuproptosis and possible targets for cancer therapy. World J Clin Oncol 2023; 14(9): 324-334
- URL: https://www.wjgnet.com/2218-4333/full/v14/i9/324.htm
- DOI: https://dx.doi.org/10.5306/wjco.v14.i9.324